Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
On December 6, 2023, Nyxoah received a transparency notification from Deerfield Partners, L.P. indicating that Deerfield Partners, L.P. crossed the 3% threshold on November 30, 2023, after which Deerfield Partners, L.P. holds 856,085 shares, representing 2.99% of the total number of voting rights on November 30, 2023 (28,673,985).
The notification dated December 6, 2023 contains the following information:
| A) Voting rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | |||
| Holders of voting rights | Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities | |
| James E. Flynn | 0 | 0 | 0 | 0.00% | 0.00% |
| Deerfield Partners, L.P. | 899,300 | 856,085 | 0 | 2.99% | 0.00% |
| Subtotal | 899,300 | 856,085 | 2.99% | ||
| TOTAL | 856,085 | 0 | 2.99% | 0.00% | |
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 310 310 1313

| Last Trade: | US$4.57 |
| Daily Change: | 0.03 0.66 |
| Daily Volume: | 111,107 |
| Market Cap: | US$196.650M |
November 13, 2025 November 13, 2025 September 23, 2025 September 02, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load